Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...

Our analysis of options history for Moderna (NASDAQ:MRNA) revealed 31 unusual trades. Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies.

Moderna (MRNA) closed the latest trading day ... Elsewhere, the Dow saw an upswing of 0.65%, while the tech-heavy Nasdaq depreciated by 3.07%. Prior to today's trading, shares of the biotechnology ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of ...

Moderna, Inc. (MRNA), headquartered in Cambridge, Massachusetts, is a leading biotechnology company committed to pioneering messenger RNA (mRNA) therapeutics and vaccines to transform the future ...

Investors in Moderna Inc (Symbol: MRNA) saw new options become available today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRNA ...

We recently compiled a list of the The 10 Worst-Performing Stocks on Monday. In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against the other stocks. Ten ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (XTRA:0QF) from Buy to Neutral. As of January 28, 2025, the average one-year price target for Moderna is ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (WBAG:MRNA) from Buy to Neutral. There are 1,449 funds or institutions reporting positions in Moderna.